



## Drug Coverage Policy

Effective Date ..... 01/01/2026

Coverage Policy Number.....IP0660

Policy Title.....Infliximab Intravenous  
Products Prior Authorization Policy

# Inflammatory Conditions – Infliximab Intravenous Products Prior Authorization Policy

- Avsola™ (infliximab-axxq intravenous infusion – Amgen)
- Inflectra® (infliximab-dyyb intravenous infusion – Hospira/Pfizer)
- Infliximab intravenous infusion – Janssen/Johnson & Johnson
- Remicade® (infliximab intravenous infusion – Janssen/Johnson & Johnson)
- Renflexis® (infliximab-abda intravenous infusion – Samsung Bioepis/Organon)

---

### **INSTRUCTIONS FOR USE**

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment where appropriate and have discretion in making individual coverage determinations. Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant criteria outlined in the applicable Coverage Policy, including covered diagnosis and/or procedure code(s). Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this Coverage Policy (see "Coding Information" below). When billing, providers must use the most appropriate codes as of the effective date of the submission. Claims submitted for services that are not accompanied by covered code(s) under the applicable Coverage Policy

*will be denied as not covered. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.*

---

## OVERVIEW

Infliximab products are tumor necrosis factor inhibitors (TNFis) approved for the following indications:<sup>1-3</sup>

- **Ankylosing spondylitis**, for reducing signs and symptoms of active disease.
- **Crohn's disease**, for the following uses:
  - Reducing the signs and symptoms and inducing and maintaining clinical remission in patients  $\geq$  6 years of age with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy; AND
  - Reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adults with fistulizing Crohn's disease.
- **Plaque psoriasis**, for treatment of adults with chronic severe (i.e., extensive and/or disabling) disease who are candidates for systemic therapy and when other systemic therapies are less appropriate.
- **Psoriatic arthritis**, for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage and improving physical function.
- **Rheumatoid arthritis**, in combination with methotrexate for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active disease.
- **Ulcerative colitis**, for the following uses:
  - Reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adults with moderately to severely active disease who have had an inadequate response to conventional therapy; AND
  - Reducing signs and symptoms and inducing and maintaining clinical remission in patients  $\geq$  6 years of age with moderately to severely active disease who have had an inadequate response to conventional therapy.

Avsola, Inflectra, and Renflexis were approved as biosimilar to Remicade, indicating no clinically meaningful differences in safety and effectiveness and the same mechanism of action, route of administration, dosage form, and strength as Remicade.<sup>2-3</sup> However, minor differences in clinically inactive components are allowed. At this time, only biosimilarity has been demonstrated (not interchangeability).

## Guidelines

TNFis feature prominently in guidelines for treatment of many inflammatory conditions.

- **Ankylosing Spondylitis and Non-Radiographic Spondyloarthritis:** Guidelines for ankylosing spondylitis and non-radiographic axial spondyloarthritis are published by the American College of Rheumatology (ACR)/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network (2019).<sup>4</sup> Following primary nonresponse to a TNFi, an interleukin (IL)-17 blocker is recommended; however, if the patient is a secondary nonresponder, a second TNFi is recommended over switching out of the class. In patients with a contraindication to a TNFi, use of an IL-17 blocker is recommended over traditional oral agents such as methotrexate or sulfasalazine.
- **Crohn's Disease:** The American College of Gastroenterology (ACG) [2025] has guidelines for the management of CD in adults.<sup>5</sup> In moderate to severe disease, systemic corticosteroids or advanced therapies may be utilized for induction of remission. Advanced therapies recommended include tumor necrosis factor (TNF) inhibitors, Entyvio® (vedolizumab), interleukin (IL)-23 inhibitors, IL-12/23 inhibitors, and Rinvoq®

(upadacitinib). If steroids are utilized for induction, efforts should be made to introduce steroid-sparing agents for maintenance therapy. Guidelines from the American Gastroenterological Association (AGA) [2021] include infliximab among the therapies for moderate to severe Crohn's disease, for induction and maintenance of remission.<sup>6</sup>

- **Plaque Psoriasis:** Guidelines from the American Academy of Dermatologists (AAD) and National Psoriasis Foundation (NPF) [2019] recommend infliximab as a monotherapy treatment option for adults with moderate to severe disease.<sup>7</sup>
- **Psoriatic Arthritis:** Guidelines from ACR (2019) recommend TNFis over other biologics for use in treatment-naïve patients with psoriatic arthritis, and in those who were previously treated with an oral therapy.<sup>8</sup>
- **Rheumatoid Arthritis:** Guidelines from ACR (2021) recommend addition of a biologic or a targeted synthetic disease modifying anti-rheumatic drug (DMARD) for a patient taking the maximum tolerated dose of methotrexate who is not at target.<sup>9</sup>
- **Ulcerative Colitis:** The AGA (2024) and the ACG (2025) have clinical practice guidelines on the management of moderate to severe UC.<sup>10,11</sup> In moderate to severe disease, systemic corticosteroids or advanced therapies may be utilized for induction of remission. Advanced therapies recommended include TNF inhibitors, Entyvio, IL-23 inhibitors, IL-12/23 inhibitors, sphingosine-1-phosphate (S1P) receptor modulators, and Janus kinase (JAK) inhibitors. If steroids are utilized for induction, efforts should be made to introduce steroid-sparing agents for maintenance therapy. Of note, guidelines state corticosteroids may be avoided entirely when other effective induction strategies are planned.<sup>11</sup> Both guidelines also recommend that any drug that effectively treats induction should be continued for maintenance.<sup>10,11</sup>
- **Behcet's Disease:** The European League Against Rheumatism (EULAR) recommendations (2018) include TNFis for initial or recurrent sight-threatening uveitis.<sup>13</sup> For patients refractory to first-line treatments (e.g., corticosteroids), TNFis are among the treatment options for mucocutaneous manifestations, venous thrombosis, severe or refractory gastrointestinal disease, and recurrent/chronic joint involvement. Recommendations for the use of TNFis in ocular inflammatory disorders from the American Academy of Ophthalmology (AAO) [2014] note that TNFis may be used first-line in patients with ophthalmic manifestations of Behcet's disease and for acute exacerbations of pre-existing Behcet's disease.<sup>14</sup>
- **Graft-Versus-Host Disease (GVHD):** Guidelines for hematopoietic cell transplantation from the National Comprehensive Cancer network (NCCN) [version 2.2025 – June 3, 2025] list infliximab among the agents used for steroid-refractory acute GVHD.<sup>15</sup> For patients with steroid-refractory acute GVHD, Jakafi® (ruxolitinib tablets) is the only category 1 recommended agent. Other alternative agents recommended by NCCN for acute GVHD (category 2A) include the following: alemtuzumab IV infusion, alpha-1 antitrypsin, anti-thymocyte globulin, Simulect® (basiliximab), calcineurin inhibitors (e.g., tacrolimus, cyclosporine), Enbrel® (etanercept), extracorporeal photopheresis, infliximab, mammalian target of rapamycin inhibitors (e.g., sirolimus), mycophenolate mofetil, Nipent™ (pentostatin), tocilizumab, urinary-derived human chorionic gonadotropin/epidermal growth factor, and Entyvio® (vedolizumab)..<sup>15</sup>
- **Hidradenitis Suppurativa:** Guidelines from the US and Canadian Hidradenitis Suppurativa Foundations make recommendations for topical, intralesional, and systemic medical management of disease.<sup>16</sup> For acute lesions of all stages, antiseptic washes, short-term oral steroids, and interlesional steroids are among the recommendations. Systemic antibiotics have been a mainstay of treatment. Infliximab is a recommended therapy for moderate to severe disease.
- **Immunotherapy-Related Toxicities Associated with Checkpoint Inhibitors:** NCCN has guidelines (version 1.2025 – December 20, 2024) for Management of Immunotherapy-Related Toxicities.<sup>17</sup> Infliximab is recommended among the alternatives to manage steroid-refractory toxicities related to immune checkpoint inhibitors including inflammatory arthritis,

uveitis, hemolytic anemia, myocarditis, stage 3 acute kidney injury/elevated serum creatinine, pneumonitis, esophagitis, gastritis, duodenitis, and diarrhea/colitis. Additionally, the guidelines also note that infliximab has not been tested and is not recommended for hepatotoxicity due to concerns of liver toxicity.

- **Indeterminate Colitis:** Infliximab has been effective in some patients with refractory indeterminate colitis (retrospective reviews).<sup>18,19</sup> When patients who are refractory to standard therapy can be definitively classified as having ulcerative colitis, colectomy is considered an effective long-term surgical treatment. Patient's with Crohn's disease; however, have a high risk of complications after ileal pouch-anal anastomosis and are treated more aggressively with medical interventions since surgical options cannot offer the same likelihood of success as in ulcerative colitis.
- **Juvenile Idiopathic Arthritis (JIA):** There are guidelines from ACR and the Arthritis Foundation for the treatment of JIA (2021) which address oligoarthritis and temporomandibular joint (TMJ) arthritis.<sup>20</sup> For oligoarthritis, a biologic is recommended following a trial of a conventional synthetic DMARD. In patients with TMJ arthritis, scheduled nonsteroidal anti-inflammatory drugs (NSAIDs) and/or intra-articular glucocorticoids are recommended first-line. A biologic is a therapeutic option if there is an inadequate response or intolerance. Additionally, rapid escalation to a biologic ± conventional synthetic DMARD (methotrexate preferred) is often appropriate given the impact and destructive nature of TMJ arthritis. In these guidelines, there is not a preferred biologic that should be initiated for JIA. The ACR/Arthritis Foundation Guideline for the treatment of JIA (2019) provides updated recommendations for juvenile non-systemic polyarthritis, sacroiliitis, and enthesitis.<sup>21</sup> Infliximab is among the TNFis recommended as subsequent therapy following treatment with a conventional synthetic DMARD such as methotrexate. TNF antagonists such as infliximab may also be used as second- or third-line treatment for systemic JIA.<sup>22</sup>
- **Ocular Inflammatory Disorders:** Recommendations for the use of TNFis in ocular inflammatory disorders from the AAO (2014) note that infliximab may be used as second-line corticosteroid-sparing therapy for chronic and severe scleritis.<sup>14</sup> Infliximab may be used in patients with uveitis due to various causes (e.g., spondyloarthropathy-associated or human leukocyte antigen [HLA]-B27-associated uveitis, juvenile idiopathic arthritis-associated uveitis, and other posterior uveitides and panuveitis syndromes). Infliximab should be considered second-line in vision-threatening JIA-associated uveitis when methotrexate has failed or is not tolerated (strong recommendation) and vision-threatening chronic uveitis from seronegative spondyloarthropathy (strong recommendation). Infliximab may also be considered in other patients who have vision-threatening or corticosteroid-dependent disease who have failed first-line therapies. The recommendations point out that studies evaluating infliximab in uveitis included patients with birdshot chorioretinitis (BSCR), a bilateral posterior uveitis generally treated with systemic immunomodulation; these patients showed a good response to infliximab.
- **Pyoderma Gangrenosum:** Although guidelines are not current, multiple topical and systemic therapies have been used for pyoderma gangrenosum. Oral prednisone is the most common initial immunosuppressant medication.<sup>23</sup> Other systemic therapies include cyclosporine, methotrexate, azathioprine, cyclophosphamide, mycophenolate mofetil, and TNFis (i.e., infliximab, etanercept, and adalimumab products). In case reports, TNFis have been effective.
- **Sarcoidosis:** The European Respiratory Society Task Force has guidelines for treatment of pulmonary, cutaneous, cardiac, and neurologic sarcoidosis.<sup>24</sup> Infliximab is a recommended therapy after continued disease or relapse while taking systemic corticosteroids and immunosuppressants (e.g., methotrexate, azathioprine, leflunomide, mycophenolate mofetil, hydroxychloroquine).
- **Still's Disease:** Still's disease presents in adults with features similar to those of systemic onset JIA.<sup>25,26</sup> In case series, infliximab has been effective in patients with Still's disease

that was refractory to therapy with corticosteroids, methotrexate, azathioprine, and cyclophosphamide.<sup>24</sup>

### Dosing Information

The recommended dose of infliximab intravenous is weight-based and varies slightly by indication.<sup>1-3</sup> Dosing increase, interval shortening, or changing to another therapy is generally recommended for attenuation of response. Thus, published recommendations note that the dose and interval of infliximab may be adjusted, as needed, in patients who initially respond but then lose that response.<sup>2</sup> Additionally, data are emerging concerning tapering of infliximab dosage in patients with inflammatory conditions who are in remission or have low disease activity. When the dose of any RA therapy is tapered, it is recommended that there be a comprehensive plan to monitor disease activity and address possible flares.

## Coverage Policy

### POLICY STATEMENT

Prior Authorization is required for benefit coverage of infliximab products. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indications. Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days. Because of the specialized skills required for evaluation and diagnosis of a patient treated with infliximab products as well as the monitoring required for adverse events and long-term efficacy, initial approval requires infliximab products to be prescribed by or in consultation with a physician who specializes in the condition being treated.

**NOTE:** This product also requires the use of preferred products before approval of a requested non-preferred infliximab intravenous product. Refer to the respective *Inflammatory Conditions – Infliximab Intravenous Products Preferred Specialty Management Policy (PSM005)* for additional preferred product criteria requirements and exceptions.

**Infliximab intravenous products are considered medically necessary when ONE of the following is met (1-18):**

### FDA-Approved Indications

**1. Ankylosing Spondylitis.** Approve for the duration noted if the patient meets ONE of the following (A or B):

- A) Initial Therapy.** Approve for 6 months if the patient meets BOTH of the following (i and ii):
- i. Patient is  $\geq$  18 years of age; AND
  - ii. The medication is prescribed by or in consultation with a rheumatologist; OR
- B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient meets BOTH of the following (i and ii):
- i. Patient has been established on therapy for at least 6 months; AND
- Note: A patient who has received < 6 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).
- ii. Patient meets at least ONE of the following (a or b):

- a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); OR  
Note: Examples of objective measures include Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), Health Assessment Questionnaire for the Spondyloarthropathies (HAQ-S), and/or serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate).
- b) Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as decreased pain or stiffness, or improvement in function or activities of daily living.

**Dosing.** Approve ONE of the following regimens (A or B):

- A) Initial Therapy. Approve up to 5 mg/kg as an intravenous infusion followed by additional similar doses at 2 and 6 weeks after the first infusion, and then no more frequently than once every 6 weeks thereafter.
- B) Patient is Currently Receiving an Infliximab Product. Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

---

**2. Crohn's Disease.** Approve for the duration noted if the patient meets ONE of the following (A or B):

- A) Initial Therapy. Approve for 6 months if the patient meets ALL of the following (i, ii, and iii):
  - i. Patient is  $\geq$  6 years of age; AND
  - ii. Patient meets ONE of the following (a, b, c, or d):
    - a) Patient has tried or is currently taking corticosteroids, or corticosteroids are contraindicated in this patient; OR  
Note: Examples of corticosteroids are prednisone and methylprednisolone.
    - b) Patient has tried one other conventional systemic therapy for Crohn's disease; OR  
Note: Examples of conventional systemic therapies for Crohn's disease include azathioprine, 6-mercaptopurine, or methotrexate. An exception to the requirement for a trial of or contraindication to steroids or a trial of one other conventional systemic agent can be made if the patient has already tried at least one biologic other than the requested medication. A biosimilar of the requested biologic does not count. Refer to Appendix for examples of biologics used for Crohn's disease. A trial of mesalamine does not count as a systemic therapy for Crohn's disease.
    - c) Patient has enterocutaneous (perianal or abdominal) or rectovaginal fistulas; OR
    - d) Patient had ileocolonic resection (to reduce the chance of Crohn's disease recurrence); AND
  - iii. The medication is prescribed by or in consultation with a gastroenterologist; OR
- B) Patient is Currently Receiving an Infliximab Product. Approve for 1 year if the patient meets BOTH of the following (i and ii):
  - i. Patient has been established on therapy for at least 6 months; AND  
Note: A patient who has received  $<$  6 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).
  - ii. Patient meets at least ONE of the following (a or b):
    - a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); OR  
Note: Examples of objective measures include fecal markers (e.g., fecal lactoferrin, fecal calprotectin), serum markers (e.g., C-reactive protein), imaging studies

- (magnetic resonance enterography [MRE], computed tomography enterography [CTE]), endoscopic assessment, and/or reduced dose of corticosteroids.
- b) Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as decreased pain, fatigue, stool frequency, and/or blood in stool.

**Dosing.** Approve ONE of the following regimens (A or B):

- A) Initial Therapy. Approve up to 5 mg/kg as an intravenous infusion followed by additional similar doses at 2 and 6 weeks after the first infusion, and then no more frequently than once every 8 weeks thereafter.
- B) Patient is Currently Receiving an Infliximab Product. Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

---

**3. Plaque Psoriasis.** Approve for the duration noted if the patient meets ONE of the following (A or B):

- A) Initial Therapy. Approve for 3 months if the patient meets ALL of the following (i, ii, and iii):
- i. Patient is  $\geq$  18 years of age; AND
  - ii. Patient meets ONE of the following (a or b):
    - a) Patient has tried at least one traditional systemic agent for psoriasis for at least 3 months, unless intolerant; OR
      - Note: Examples include methotrexate, cyclosporine, or acitretin (Soriatane<sup>®</sup>, generics). A 3-month trial of psoralen plus ultraviolet A light (PUVA) also counts. An exception to the requirement for a trial of one traditional systemic agent for psoriasis can be made if the patient already had a 3-month trial or previous intolerance to at least one biologic (other than the requested medication), Otezla/Otezla XR (apremilast tablets/extended-release tablets), or Sotyktu (deucravacitinib tablets). A biosimilar of the requested biologic does not count. Refer to Appendix for examples of biologics used for plaque psoriasis. A patient who has already tried a biologic, Otezla/Otezla XR, or Sotyktu for plaque psoriasis is not required to "step back" and try a traditional systemic agent for plaque psoriasis.
    - b) According to the prescriber, the patient has a contraindication to methotrexate; AND
  - iii. The medication is prescribed by or in consultation with a dermatologist; OR

- B) Patient is Currently Receiving an Infliximab Product. Approve for 1 year if the patient meets ALL of the following (i, ii, and iii):
- i. Patient has been established on therapy for at least 3 months; AND
    - Note: A patient who has received < 3 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).
  - ii. Patient experienced a beneficial clinical response, defined as improvement from baseline (prior to initiating an infliximab product) in at least one of the following: estimated body surface area affected, erythema, induration/thickness, and/or scale of areas affected by psoriasis; AND
  - iii. Compared with baseline (prior to receiving an infliximab product), patient experienced an improvement in at least one symptom, such as decreased pain, itching, and/or burning.

**Dosing.** Approve ONE of the following regimens (A or B):

- A) Initial Therapy. Approve up to 5 mg/kg as an intravenous infusion followed by additional similar doses at 2 and 6 weeks after the first infusion, and then no more frequently than once every 8 weeks thereafter.

**B)** Patient is Currently Receiving an Infliximab Product. Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

---

**4. Psoriatic Arthritis.** Approve for the duration noted if the patient meets ONE of the following (A or B):

**A) Initial Therapy.** Approve for 6 months if the patient meets BOTH of the following (i and ii):

- i. Patient is  $\geq$  18 years of age; AND
- ii. The medication is if prescribed by or in consultation with a rheumatologist or a dermatologist; OR

**B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient meets BOTH of the following (i and ii):

- iii. Patient has been established on therapy for at least 6 months; AND

Note: A patient who has received < 6 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).

- iv. Patient meets at least ONE of the following (a or b):

a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); OR  
Note: Examples of objective measures of disease activity include Disease Activity Index for Psoriatic Arthritis (DAPSA), Composite Psoriatic Disease Activity Index (CPDAI), Psoriatic Arthritis Disease Activity Score (PsA DAS), Grace Index, Leeds Enthesitis Score (LEI), Spondyloarthritis Consortium of Canada (SPARCC) enthesitis score, Leeds Dactylitis Instrument Score, Minimal Disease Activity (MDA), Psoriatic Arthritis Impact of Disease (PsAID-12), and/or serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate).

b) Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as less joint pain, morning stiffness, or fatigue; improved function or activities of daily living; or decreased soft tissue swelling in joints or tendon sheaths.

**Dosing.** Approve ONE of the following regimens (A or B):

**A) Initial Therapy.** Approve up to 5 mg/kg as an intravenous infusion followed by additional similar doses 2 and 6 weeks after the first infusion, and then no more frequently than once every 8 weeks thereafter.

**B) Patient is Currently Receiving an Infliximab Product.** Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

---

**5. Rheumatoid Arthritis.** Approve for the duration noted if the patient meets ONE of the following (A or B):

**A) Initial Therapy.** Approve for 6 months if the patient meets ALL of the following (i, ii, and iii):

- i. Patient is  $\geq$  18 years of age; AND
- ii. Patient has tried ONE conventional synthetic disease-modifying antirheumatic drug (DMARD) for at least 3 months; AND

Note: Examples include methotrexate (oral or injectable), leflunomide, hydroxychloroquine, and sulfasalazine. An exception to the requirement for a trial of one conventional synthetic DMARD can be made if the patient already had a 3-month trial of at least one biologic other than the requested medication. A biosimilar of the requested biologic does not count. Refer to Appendix for examples of biologics used for rheumatoid arthritis. A patient who has already tried a biologic is not required to "step back" and try a conventional synthetic DMARD.

- ii. The medication is prescribed by or in consultation with a rheumatologist; OR

**B)** Patient is Currently Receiving an Infliximab Product. Approve for 1 year if the patient meets BOTH of the following (i and ii):

- i. Patient has been established on therapy for at least 6 months; AND

Note: A patient who has received < 6 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).

- ii. Patient meets at least ONE of the following (a or b):

- a) Patient experienced a beneficial clinical response when assessed by at least one objective measure; OR

Note: Examples of objective measures of disease activity include Clinical Disease Activity Index (CDAI), Disease Activity Score (DAS) 28 using erythrocyte sedimentation rate or C-reactive protein, Patient Activity Scale (PAS)-II, Rapid Assessment of Patient Index Data 3 (RAPID-3), and/or Simplified Disease Activity Index (SDAI).

- b) Patient experienced an improvement in at least one symptom, such as decreased joint pain, morning stiffness, or fatigue; improved function or activities of daily living; or decreased soft tissue swelling in joints or tendon sheaths.

**Dosing.** Approve ONE of the following regimens (A or B):

**A)** Initial Therapy. Approve up to 3 mg/kg as an intravenous infusion followed by additional similar doses at 2 and 6 weeks after the first infusion, and then no more frequently than once every 8 weeks thereafter.

**B)** Patient is Currently Receiving an Infliximab Product. Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

---

**6. Ulcerative Colitis.** Approve for the duration noted if the patient meets ONE of the following (A or B):

**A)** Initial Therapy. Approve for 6 months if the patient meets BOTH of the following (i and ii):

- i. Patient is  $\geq$  6 years of age; AND

- ii. The medication is prescribed by or in consultation with a gastroenterologist; OR

**B)** Patient is Currently Receiving an Infliximab Product. Approve for 1 year if the patient meets BOTH of the following (i and ii):

- i. Patient has been established on therapy for at least 6 months; AND

Note: A patient who has received < 6 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).

- ii. Patient meets at least ONE of the following (a or b):

- a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); OR  
Note: Examples of objective measures include fecal markers (e.g., fecal calprotectin), serum markers (e.g., C-reactive protein), endoscopic assessment, and/or reduced dose of corticosteroids.

- b) Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as decreased pain, fatigue, stool frequency, and/or rectal bleeding.

**Dosing.** Approve ONE of the following regimens (A or B):

**A)** Initial Therapy. Approve up to 5 mg/kg as an intravenous infusion followed by additional similar doses 2 and 6 weeks after the first infusion, and then no more frequently than once every 8 weeks thereafter.

**B)** Patient is Currently Receiving an Infliximab Product. Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

## **Other Uses with Supportive Evidence**

---

**7. Behcet's Disease.** Approve for the duration noted if the patient meets ONE of the following (A or B):

**A) Initial Therapy.** Approve for 3 months if the patient meets ALL of the following (i, ii, and iii):

- i. Patient is  $\geq$  6 years of age; AND
- ii. Patient meets ONE of the following (a or b):

a) Patient has tried at least ONE conventional therapy; OR

Note: Examples include systemic corticosteroids (e.g., methylprednisolone), immunosuppressants (azathioprine, methotrexate, mycophenolate mofetil, cyclosporine, tacrolimus, Leukeran® [chlorambucil tablet], cyclophosphamide, interferon alfa). An exception to the requirement for a trial of one conventional therapy can be made if the patient has already had a trial of at least one tumor necrosis factor inhibitor (e.g., an adalimumab product, an etanercept product). A patient who has already tried one biologic other than the requested drug for Behcet's disease is not required to "step back" and try a conventional therapy. A biosimilar of the requested biologic does not count.

b) Patient has ophthalmic manifestations of Behcet's disease; AND

iii. The medication is prescribed by or in consultation with a rheumatologist, dermatologist, ophthalmologist, gastroenterologist, or neurologist; OR

**A) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient meets ALL of the following (i, ii, and iii):

i. Patient has been established on therapy for at least 3 months; AND

Note: A patient who has received < 3 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).

ii. When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); AND

Note: Examples of objective measures are dependent upon organ involvement but may include best-corrected visual acuity (if ophthalmic manifestations); serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate); or ulcer depth, number, and/or lesion size.

iii. Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as decreased pain or improved visual acuity (if ophthalmic manifestations).

**Dosing.** Approve ONE of the following regimens (A or B):

**A) Initial Therapy.** Approve up to 5 mg/kg as an intravenous infusion followed by additional similar doses at 2 and 6 weeks after the first infusion, then no more frequently than once every 6 weeks thereafter.

**B) Patient is Currently Receiving an Infliximab Product.** Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

---

**8. Graft-Versus-Host Disease.** Approve for the duration noted if the patient meets ONE of the following (A or B):

**A) Initial Therapy.** Approve for 1 month if the patient meets ALL of the following (i, ii, and iii):

i. Patient is  $\geq$  6 years of age; AND

ii. Patient has acute graft-versus-host disease; AND

iii. Patient has tried at least one systemic medication for graft-versus-host disease; AND

Note: Examples of systemic medications include corticosteroids (e.g., methylprednisolone), antithymocyte globulin, cyclosporine, tacrolimus, mycophenolate

mofetil, Jakafi (ruxolitinib), Simulect (basiliximab), an etanercept product, sirolimus, Nipent (pentostatin), a tocilizumab product, and Entyvio (vedolizumab).

- iv.** The medication is prescribed by or in consultation with an oncologist, hematologist, or a physician affiliated with a transplant center; OR

- B)** Patient is Currently Receiving an Infliximab Product. Approve for 3 months if the patient meets BOTH of the following (i and ii):

- i. Patient has been established on an infliximab product for at least 1 month; AND  
Note: A patient who has received < 1 month of therapy or who is restarting therapy is reviewed under criterion A (Initial Therapy).

- ii. Patient meets at least ONE of the following (a or b):

- a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); OR  
Note: An example of objective measures is normalization of liver function tests, red blood cell count, or platelet count, or resolution of fever or rash.
- b) Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as improvement in skin, oral mucosal, ocular, or gastrointestinal symptoms (e.g., nausea, vomiting, anorexia).

**Dosing.** Approve the following regimens (A and B):

- A)** The dose is up to 10 mg/kg given intravenously; AND

- B)** Doses are administered no more frequently than once weekly.

- 
- 9. Hidradenitis Suppurativa.** Approve for the duration noted if the patient meets ONE of the following (A or B):

- A)** Initial Therapy. Approve for 3 months if the patient meets ALL of the following (i, ii, and iii):

- i. Patient is  $\geq$  18 years of age; AND  
ii. Patient has tried one other therapy; AND

Note: Examples include intralesional or oral corticosteroids (e.g., triamcinolone, prednisone), systemic antibiotics (e.g., clindamycin, dicloxacillin, erythromycin), and isotretinoin.

- iii. The medication is prescribed by or in consultation with a dermatologist; OR

- B)** Patient is Currently Receiving an Infliximab Product. Approve for 1 year if the patient meets ALL of the following (i, ii, and iii):

- i. Patient has been established on therapy for at least 3 months; AND

Note: A patient who has received < 3 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).

- ii. When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); AND  
Note: Examples of objective measures include Hurley staging, Sartorius score, Physician Global Assessment, and Hidradenitis Suppurativa Severity Index.

- iii. Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as decreased pain or drainage of lesions, nodules, or cysts.

**Dosing.** Approve ONE of the following regimens (A or B):

- A)** Initial Therapy. Approve up to 5 mg/kg as an intravenous infusion followed by additional similar doses 2 and 6 weeks after the first infusion, and then no more frequently than once every 8 weeks thereafter.

- B)** Patient is Currently Receiving an Infliximab Product. Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

---

**10. Immunotherapy-Related Toxicities Associated with Checkpoint Inhibitor Therapy.**

Approve for the duration noted if the patient meets ONE of the following (A or B):

Note: Examples of checkpoint inhibitors include Keytruda (pembrolizumab intravenous [IV] infusion), Opdivo (nivolumab IV infusion), Yervoy (ipilimumab IV infusion), Tecentriq (atezolizumab IV infusion), Bavencio (avelumab IV infusion), or Imfinzi (durvalumab IV infusion).

**A) Initial Therapy.** Approve for 6 months if the patient meets ALL of the following (i, ii, iii, iv, and v):

- i. Patient is  $\geq$  18 years of age; AND
- ii. According to the prescriber, patient developed an immunotherapy-related toxicity other than hepatitis; AND
- iii. Patient developed this immunotherapy related toxicity while receiving a checkpoint inhibitor; AND
- iv. Patient has tried one systemic corticosteroid; AND  
Note: Examples include methylprednisolone and prednisone.
- v. The medication is prescribed by or in consultation with an oncologist, cardiologist, gastroenterologist, hematologist, nephrologist, pulmonologist, rheumatologist, or ophthalmologist; OR

**B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient meets BOTH of the following (i and ii):

- i. Patient has been established on therapy for at least 6 months; AND

Note: A patient who has received < 6 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).

- ii. Patient meets at least ONE of the following (a or b):

a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); OR  
Note: Examples of objective measures are dependent upon organ involvement but may include clinically significant improvement or normalization of serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate), fecal markers (e.g., fecal calprotectin), and/or reduced dosage of corticosteroids.

b) Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as less joint pain/tenderness, stiffness or swelling (if joint symptoms), stool frequency and/or rectal bleeding (if gastrointestinal symptoms), and/or improved function or activities of daily living.

**Dosing.** Approve ONE of the following regimens (A or B):

**A) Initial Therapy.** Approve up to 10 mg/kg as an intravenous infusion followed by additional similar doses at 2 and 6 weeks after the first infusion, then no more frequently than once every 4 weeks thereafter.

**B) Patient is Currently Receiving an Infliximab Product.** Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

---

**11. Indeterminate Colitis.** Approve for the duration noted if the patient meets ONE of the following (A or B):

Note: Indeterminate colitis is defined as colitis that cannot be classified with certainty as either ulcerative colitis or Crohn's disease.

**A) Initial Therapy.** Approve for 6 months if the patient meets ALL of the following (i, ii, iii, iv, and v):

- i. Patient is  $\geq$  6 years of age; AND
- ii. Patient has tried one systemic corticosteroid; AND  
Note: Examples include prednisone and methylprednisolone.

- iii. Patient has tried mesalamine; AND
    - iv. Patient has tried either azathioprine or 6-mercaptopurine; AND
    - v. The medication is prescribed by or in consultation with a gastroenterologist; OR
- B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient meets BOTH of the following (i and ii):
  - ii. Patient has been established on therapy for at least 6 months; AND
    - Note: A patient who has received < 6 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).
  - iii. Patient meets at least ONE of the following (a or b):
    - a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); OR
      - Note: Examples of objective measures include fecal markers (e.g., fecal calprotectin), serum markers (e.g., C-reactive protein), endoscopic assessment, and/or reduced dose of corticosteroids.
    - b) Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as decreased pain, fatigue, stool frequency, and/or rectal bleeding.

**Dosing.** Approve ONE of the following regimens (A or B):

- A) Initial Therapy.** Approve up to 5 mg/kg as an intravenous infusion followed by additional similar doses at 2 and 6 weeks after the first infusion, and then no more frequently than once every 8 weeks thereafter.
- B) Patient is Currently Receiving an Infliximab Product.** Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

---

**12. Juvenile Idiopathic Arthritis (JIA).** Approve for the duration noted if the patient meets ONE of the following (A or B):

Note: This includes JIA regardless of type of onset, including a patient with juvenile spondyloarthropathy/active sacroiliac arthritis. JIA is also referred to as Juvenile Rheumatoid Arthritis.

- A) Initial Therapy.** Approve for 6 months if the patient meets ALL of the following (i, ii, and iii):
  - i. Patient is  $\geq$  6 years of age; AND
  - ii. Patient meets ONE of the following (a or b):
    - a) Patient has tried one other systemic medication for this condition; OR
      - Note: Examples of other medications for JIA include methotrexate, sulfasalazine, or leflunomide, a nonsteroidal anti-inflammatory drug (NSAID) [e.g., ibuprofen, naproxen]. A previous trial of one biologic other than the requested medication also counts as a trial of one medication. A biosimilar of the requested biologic does not count. Refer to Appendix for examples of biologics used for JIA.
    - b) Patient has aggressive disease, as determined by the prescriber; AND
  - iii. The medication is prescribed by or in consultation with a rheumatologist; OR
- B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient meets BOTH of the following (i and ii):
  - i. Patient has been established on therapy for at least 6 months; AND
    - Note: A patient who has received < 6 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).
  - ii. Patient meets at least ONE of the following (a or b):
    - a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); OR
      - Note: Examples of objective measures include Physician Global Assessment (MD global), Parent/Patient Global Assessment of Overall Well-Being (PGA),

Parent/Patient Global Assessment of Disease Activity (PDA), Juvenile Arthritis Disease Activity Score (JDAS), Clinical Juvenile Arthritis Disease Activity Score (cJDAS), Juvenile Spondyloarthritis Disease Activity Index (JSpADA), serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate), and/or reduced dosage of corticosteroids.

- b)** Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as improvement in limitation of motion, less joint pain or tenderness, decreased duration of morning stiffness or fatigue, or improved function or activities of daily living.

**Dosing.** Approve ONE of the following regimens (A or B):

- A) Initial Therapy.** Approve up to 6 mg/kg as an intravenous infusion followed by additional similar doses at 2 and 6 weeks after the first infusion, and then no more frequently than once every 8 weeks thereafter.
- B) Patient is Currently Receiving an Infliximab Product.** Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

---

**13. Pyoderma Gangrenosum.** Approve for the duration noted if the patient meets ONE of the following (A or B):

- A) Initial Therapy.** Approve for 4 months if the patient meets ALL of the following (i, ii, and iii):
- i. Patient is  $\geq$  18 years of age; AND
  - ii. Patient meets ONE of the following conditions (a or b):
    - a) Patient has tried one systemic corticosteroid; OR  
Note: Examples include prednisone and methylprednisolone.
    - b) Patient has tried one other immunosuppressant for at least 2 months or was intolerant to one of these medications; AND  
Note: Examples include mycophenolate mofetil and cyclosporine.
  - iii. The medication is prescribed by or in consultation with a dermatologist; OR
- B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient meets ALL of the following (i, ii, and iii):
- i. Patient has been established on therapy for at least 4 months; AND  
Note: A patient who has received < 4 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).
  - ii. Patient experienced a beneficial clinical response, defined as improvement from baseline (prior to initiating an infliximab product) in at least one of the following: size, depth, and/or number of lesions; AND
  - iii. Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as decreased pain and/or tenderness of affected lesions.

**Dosing.** Approve ONE of the following regimens (A or B):

- A) Initial Therapy.** Approve up to 5 mg/kg as an intravenous infusion followed by additional similar doses 2 and 6 weeks after the first infusion, and then no more frequently than once every 8 weeks thereafter.
- B) Patient is Currently Receiving an Infliximab Product.** Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

---

**14. Sarcoidosis.** Approve for the duration noted if the patient meets ONE of the following (A or B):

- A) Initial Therapy.** Approve for 3 months if the patient meets ALL of the following (i, ii, iii, and iv):
- i. Patient is  $\geq$  18 years of age; AND
  - ii. Patient has tried at least one corticosteroid; AND  
Note: Examples include prednisone and methylprednisolone.
  - iii. Patient has tried at least one immunosuppressive medication; AND  
Note: Examples include methotrexate, azathioprine, leflunomide, mycophenolate mofetil, hydroxychloroquine, or chloroquine.
  - iv. The medication is prescribed by or in consultation with a pulmonologist, ophthalmologist, cardiologist, neurologist, or dermatologist; OR
- B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient meets ALL of the following (i, ii, and iii):
- i. Patient has been established on therapy for at least 3 months; AND  
Note: A patient who has received < 3 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).
  - ii. When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); AND  
Note: Examples of objective measures are dependent upon organ involvement but may include lung function (e.g., predicted forced vital capacity and/or 6-minute walk distance); serum markers (e.g., C-reactive protein, liver enzymes, N-terminal pro-brain natriuretic peptide [NT-proBNP]); improvement in rash or skin manifestations, neurologic symptoms, or rhythm control; or imaging (e.g., if indicated, chest radiograph, magnetic resonance imaging [MRI], or echocardiography).
  - iii. Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as decreased cough, fatigue, pain, palpitations, neurologic symptoms, and/or shortness of breath.

**Dosing.** Approve ONE of the following regimens (A or B):

- A) Initial Therapy.** Approve up to 5 mg/kg as an intravenous infusion followed by additional similar doses at 2 and 6 weeks after the first infusion, then no more frequently than once every 6 weeks thereafter.
- B) Patient is Currently Receiving an Infliximab Product.** Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

---

**15. Scleritis or Sterile Corneal Ulceration.** Approve for the duration noted if the patient meets ONE of the following (A or B):

- A) Initial Therapy.** Approve for 6 months if the patient meets ALL of the following (i, ii, and iii):
- i. Patient is  $\geq$  18 years of age; AND
  - ii. Patient has tried one other therapy for this condition; AND  
Note: Examples include oral non-steroidal anti-inflammatory drugs (NSAIDs) such as indomethacin; oral, topical (ophthalmic) or intravenous corticosteroids (such as prednisone, prednisolone, methylprednisolone); methotrexate; cyclosporine; or other immunosuppressants.
  - iii. The medication is prescribed by or in consultation with an ophthalmologist; OR
- B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient meets BOTH of the following (i and ii):
- i. Patient has been established on therapy for at least 6 months; AND  
Note: A patient who has received < 6 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).
  - ii. Patient meets at least ONE of the following (a or b):

- a)** When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); OR  
Note: Examples of objective measures are serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate).
- b)** Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as decreased eye pain, redness, light sensitivity, tearing, and/or improvement in visual acuity.

**Dosing.** Approve ONE of the following regimens (A or B):

- A) Initial Therapy.** Approve up to 10 mg/kg as an intravenous infusion administered at baseline and followed by up to three additional similar doses (for example, up to three additional doses given 2, 6, and 8 weeks after the initial infusion).
- B) Patient is Currently Receiving an Infliximab Product.** Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

---

**16. Spondyloarthritis, Other Subtypes** Approve for the duration noted if the patient meets

ONE of the following (A or B):

Note: Examples of other subtypes include undifferentiated arthritis, non-radiographic axial spondylitis, Reactive Arthritis [Reiter's disease]. For ankylosing spondylitis or psoriatic arthritis, refer to the respective criteria under FDA-approved indications.

- A) Initial Therapy.** Approve for 6 months if the patient meets ALL of the following (i, ii, and iii):
  - i. Patient is  $\geq$  18 years of age; AND
  - ii. Patient meets ONE of the following (a or b):
    - a)** Patient has arthritis primarily in the knees, ankles, elbows, wrists, hands, and/or feet AND has tried at least ONE conventional synthetic disease-modifying antirheumatic drug (DMARD); OR  
Note: Examples include methotrexate, leflunomide, and sulfasalazine.
    - b)** Patient has axial spondyloarthritis with objective signs of inflammation, defined as at least one of the following [(1) or (2)]:
      - (1)C-reactive protein elevated beyond the upper limit of normal for the reporting laboratory; OR
      - (2)Sacroiliitis reported on magnetic resonance imaging; AND
  - iii. The medication is prescribed by or in consultation with a rheumatologist; OR
- B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient meets BOTH of the following (i and ii):
  - i. Patient has been established on therapy for at least 6 months; AND  
Note: A patient who has received < 6 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).
  - ii. Patient meets at least ONE of the following (a or b):
    - a)** When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); OR  
Note: Examples of objective measures include Ankylosing Spondylitis Disease Activity Score (ASDAS) and/or serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate).
    - b)** Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as decreased pain or stiffness, or improvement in function or activities of daily living.

**Dosing.** Approve ONE of the following regimens (A or B):

- A) Initial Therapy.** Approve up to 5 mg/kg as an intravenous infusion followed by additional similar doses at 2 and 6 weeks after the first infusion, and then no more frequently than once every 6 weeks thereafter.
- B) Patient is Currently Receiving an Infliximab Product.** Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

---

**17. Still's Disease.** Approve for the duration noted if the patient meets ONE of the following (A or B):

- A) Initial Therapy.** Approve for 6 months if the patient meets ALL of the following (i, ii, iii, and iv):
- i. Patient is  $\geq$  18 years of age; AND
  - ii. Patient has tried one corticosteroid; AND  
Note: Examples include prednisone and methylprednisolone.
  - iii. Patient has tried one conventional synthetic disease-modifying antirheumatic drug (DMARD) given for at least 2 months or was intolerant; AND  
Note: An example is methotrexate. A previous trial of one biologic other than the requested drug (e.g., Actemra [tocilizumab intravenous injection, tocilizumab subcutaneous injection], Arcalyst [rilonacept subcutaneous injection], Ilaris [canakinumab subcutaneous injection]) also counts towards this requirement for previous therapy for Still's disease. A biosimilar of the requested biologic does not count.
  - iv. The medication is prescribed by or in consultation with a rheumatologist; OR
- B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient meets BOTH of the following (i and ii):
- i. Patient has been established on this medication for at least 6 months; AND  
Note: A patient who has received < 6 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).
  - ii. Patient meets at least ONE of the following (a or b):
    - a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); OR  
Note: Examples of objective measures include resolution of fever, improvement in rash or skin manifestations, clinically significant improvement or normalization of serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate), and/or reduced dosage of corticosteroids.
    - b) Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as less joint pain/tenderness, stiffness, or swelling; decreased fatigue; improved function or activities of daily living.

**Dosing.** Approve ONE of the following regimens (A or B):

- A) Initial Therapy.** Approve up to 6 mg/kg as an intravenous fusion followed by additional similar doses at 2 and 6 weeks after the first infusion, and then no more frequently than once every 8 weeks thereafter.
- B) Patient is Currently Receiving an Infliximab Product.** Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

---

**18. Uveitis.** Approve for the duration noted if the patient meets ONE of the following (A or B):

Note: This includes other posterior uveitides and panuveitis syndromes.

- A) Initial Therapy.** Approve for 6 months if the patient meets ALL of the following (i, ii, and iii):
- i. Patient is  $\geq$  6 years of age; AND

- ii. Patient has tried one of the following therapies: periocular, intraocular, or systemic corticosteroids, or immunosuppressives; AND

Note: Examples of corticosteroids include prednisolone, triamcinolone, betamethasone, methylprednisolone, prednisone. Examples of immunosuppressives include methotrexate, mycophenolate mofetil, and cyclosporine. An exception to the requirement for a trial of one of these therapies can be made if the patient has already had a trial of an etanercept product or an adalimumab product for uveitis. A patient who has already tried one biologic other than the requested medication also counts. A biosimilar of the requested biologic does not count.

- iii. The medication is prescribed by or in consultation with an ophthalmologist; OR

- B) Patient is Currently Receiving an Infliximab Product.** Approve for 1 year if the patient meets BOTH of the following (i and ii):

- i. Patient has been established on therapy for at least 6 months; AND

Note: A patient who has received < 6 months of therapy or who is restarting therapy with an infliximab product is reviewed under criterion A (Initial Therapy).

- ii. Patient meets at least ONE of the following (a or b):

- a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating an infliximab product); OR

Note: Examples of objective measures include best-corrected visual acuity, assessment of chorioretinal and/or inflammatory retinal vascular lesions, or anterior chamber cell grade or vitreous haze grade.

- b) Compared with baseline (prior to initiating an infliximab product), patient experienced an improvement in at least one symptom, such as decreased eye pain, redness, light sensitivity, and/or blurred vision; or improvement in visual acuity.

**Dosing.** Approve ONE of the following regimens (A or B):

- A) Initial Therapy.** Approve up to 10 mg/kg as an intravenous infusion followed by additional similar doses at 2 and 6 weeks after the first infusion, then no more frequently than once every 4 weeks thereafter.

- B) Patient is Currently Receiving an Infliximab Product.** Approve up to a maximum dose of 10 mg/kg administered intravenously no more frequently than once every 4 weeks.

## Conditions Not Covered

**Infliximab intravenous products for any other use are considered not medically necessary, including the following (this list may not be all inclusive; criteria will be updated as new published data are available):**

### 1. Concurrent Use with a Biologic or with a Targeted Synthetic Oral Small Molecule Drug.

This medication should not be administered in combination with another biologic or with a targeted synthetic oral small molecule drug used for an inflammatory condition (see [Appendix](#) for examples). Combination therapy is generally not recommended due to a potentially higher rate of adverse events and lack of controlled clinical data supporting additive efficacy.

Note: This does NOT exclude the use of conventional synthetic disease-modifying antirheumatic drug (e.g., methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine) in combination with this medication.

## Coding Information

- 1) This list of codes may not be all-inclusive.

- 2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

HCPCS Codes	Description
J1745	Injection, infliximab, excludes biosimilar, 10 mg
Q5103	Injection, infliximab-dyyb, biosimilar, (Inflectra), 10 mg
Q5104	Injection, infliximab-abda, biosimilar, (Renflexis), 10 mg
Q5121	Injection, infliximab-axxq, biosimilar, (Avsola), 10 mg

## References

1. Infliximab intravenous infusion [prescribing information]. Horsham, PA: Janssen; October 2021.
2. Inflectra injection [prescribing information]. Lake Forest, IL: Hospira/Pfizer; June 2021.
3. Renflexis injection [prescribing information]. Jersey City, NJ: Samsung Bioepis/Organon; December 2023.
4. Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis Rheumatol.* 2019;10(10):1599-1613.
5. Lichtenstein G, Loftus E, Afzali A, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol.* 2025 June;120(6):1225-1264.
6. Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. *Gastroenterology.* 2021;160(7):2496-2508.
7. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol.* 2019;80(4):1029-1072.
8. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. *Arthritis Care Res (Hoboken).* 2019;71(1):2-29.
9. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol.* 2021;73(7):1108-1123.
10. Singh S, Loftus EV Jr, Limketkai BN, et al. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. *Gastroenterology.* 2024 Dec;167(7):1307-1343.
11. Rubin D, Ananthakrishnan A, Siegel C. ACG Clinical Guideline Update: Ulcerative Colitis in Adults. *Am J of Gastroenterol.* 2025 June;120(6):1187-1224.
12. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome. *Ann Rheum Dis.* 2018;77(6):808-818.
13. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. *Ophthalmology.* 2014;121(3):785-796.
14. The NCCN Hematopoietic Cell Transplantation (HCT) Clinical Practice Guidelines in Oncology (version 2.2025 – June 5, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on July 14, 2025.
15. Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis

- Suppurativa Foundations: Part II: topical, intralesional, and systemic medical management. *J Am Acad Dermatol.* 2019;81(1):91-101.
17. The NCCN Management of Immunotherapy-Related Toxicities Clinical Practice Guidelines in Oncology (version 1.2025 – December 20, 2024). © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed July 14, 2025.
  18. Papadakis KA, Treyzon L, Abreu MT, et al. Infliximab in the treatment of medically refractory indeterminate colitis. *Aliment Pharmacol Ther.* 2003;18:741-747.
  19. Gornet JM, Couve S, Hassani Z, et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. *Aliment Pharmacol Ther.* 2003;18:175-181.
  20. Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. *Arthritis Rheumatol.* 2022 Apr;74(4):553-569.
  21. Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. *Arthritis Rheumatol.* 2019;71(6):846-863.
  22. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. *Arthritis Rheum.* 2013;65(10):2499-2512.
  23. Dabade TS, Davis MD. Diagnosis and treatment of the neutrophilic dermatoses (pyoderma gangrenosum, Sweet's syndrome). *Dermatol Ther.* 2011;24(2):273-284.
  24. Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. *Eur Respir J.* 2021;58(6):2004079.
  25. Riera E, Olivé A, Narváez J, et al. Adult onset Still's disease: review of 41 cases. *Clin Exp Rheumatol.* 2011;29(2):331-336.
  26. Pouchot J, Arlet JB. Biological treatment in adult-onset Still's disease. *Best Pract Res Clin Rheumatol.* 2012;26(4):477-487.
  27. Kontzias A, Efthimiou P. Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances. *Drugs.* 2008;68:319-337.

## Revision Details

Type of Revision	Summary of Changes	Date
New	New policy	11/01/2024
Annual Revision	<b>Immunotherapy-Related Toxicities Associated with Checkpoint Inhibitor Therapy:</b> Myalgia and myositis were removed from the examples of immunotherapy-related toxicities associated with checkpoint inhibitor therapy.	02/15/2025
Selected Revision	<b>Ulcerative Colitis:</b> For initial therapy, removed the following options of approval: (1) the patient has tried one systemic therapy; (2) the patient has pouchitis and tried an antibiotic, probiotic, corticosteroid enema, or mesalamine enema.	09/01/2025
Selected Revision	<b>Graft-versus-Host Disease:</b> For initial approvals, added the requirement that patient has acute graft-versus-host disease. Modified the requirement that	10/15/2025

	<p>patient has tried at least one conventional systemic treatment to at least one systemic medication. Jakafi (ruxolitinib), Simulect (basiliximab), an etanercept product, sirolimus, Nipent (pentostatin), a tocilizumab product, and Entyvio (vedolizumab) were added to the Note of examples of systemic medications.</p> <p><b>Immunotherapy-Related Toxicities Associated with Checkpoint Inhibitor Therapy:</b></p> <p>"According to the prescriber" was added to the requirement that patient experienced an immunotherapy-related toxicity while receiving a checkpoint inhibitor and specific examples of immunotherapy-related toxicities were removed. Cardiologist, hematologist, nephrologist, and pulmonologist were added as accepted specialists to the specialist requirement.</p>	
Early Annual Revision	<p><b>Plaque Psoriasis:</b> For initial therapy, in the Note, a 3-month trial or prior intolerance to Otezla/Otezla XR (apremilast tablets/extended-release tablets), or Sotyktu (deucravacitinib tablets) was added as an exception to the requirement for a trial of one traditional systemic agent for psoriasis. For initial therapy, the requirement "patient has a contraindication to methotrexate, as determined by the prescriber" was modified to "according to the prescriber, the patient has a contraindication to methotrexate". In the Appendix, Otezla XR (apremilast extended-release tablets) was added under the Oral Therapies/Targeted Synthetic Oral Small Molecular Drugs.</p>	01/01/2026

The policy effective date is in force until updated or retired.

## APPENDIX

	Mechanism of Action	Examples of Indications*
<b>Biologics</b>		
<b>Adalimumab SC Products</b> (Humira®, biosimilars)	Inhibition of TNF	AS, CD, JIA, PsO, PsA, RA, UC
<b>Cimzia®</b> (certolizumab pegol SC injection)	Inhibition of TNF	AS, CD, nr-axSpA, PsO, PsA, RA
<b>Etanercept SC Products</b> (Enbrel®, biosimilars)	Inhibition of TNF	AS, JIA, PsO, PsA, RA
<b>Infliximab IV Products</b> (Remicade®, biosimilars)	Inhibition of TNF	AS, CD, PsO, PsA, RA, UC
<b>Zymfentra®</b> (infliximab-dyyb SC injection)	Inhibition of TNF	CD, UC
<b>Simponi®, Simponi Aria®</b> (golimumab SC injection, golimumab IV infusion)	Inhibition of TNF	SC formulation: AS, PsA, RA, UC

		IV formulation: AS, PJIA, PsA, RA
<b>Tocilizumab Products</b> (Actemra® IV, biosimilar; Actemra SC, biosimilar)	Inhibition of IL-6	SC formulation: PJIA, RA, SJIA
		IV formulation: PJIA, RA, SJIA
<b>Kevzara®</b> (sarilumab SC injection)	Inhibition of IL-6	RA
<b>Orencia®</b> (abatacept IV infusion, abatacept SC injection)	T-cell costimulation modulator	SC formulation: JIA, PSA, RA
		IV formulation: JIA, PsA, RA
<b>Rituximab IV Products</b> (Rituxan®, biosimilars)	CD20-directed cytolytic antibody	RA
<b>Kineret®</b> (anakinra SC injection)	Inhibition of IL-1	JIA^, RA
<b>Omwoh®</b> (mirikizumab IV infusion, SC injection)	Inhibition of IL-23	CD, UC
<b>Ustekinumab Products</b> (Stelara® IV, biosimilar; Stelara SC, biosimilar)	Inhibition of IL-12/23	SC formulation: CD, PsO, PsA, UC
		IV formulation: CD, UC
<b>Siliq®</b> (brodalumab SC injection)	Inhibition of IL-17	PsO
<b>Cosentyx®</b> (secukinumab SC injection; secukinumab IV infusion)	Inhibition of IL-17A	SC formulation: AS, ERA, nr-axSpA, PsO, PsA
		IV formulation: AS, nr-axSpA, PsA
<b>Taltz®</b> (ixekizumab SC injection)	Inhibition of IL-17A	AS, nr-axSpA, PsO, PsA
<b>Bimzelx®</b> (bimekizumab-bkzx SC injection)	Inhibition of IL-17A/17F	PsO, AS, nr-axSpA, PsA
<b>Ilumya®</b> (tildrakizumab-asmn SC injection)	Inhibition of IL-23	PsO
<b>Skyrizi®</b> (risankizumab-rzaa SC injection, risankizumab-rzaa IV infusion)	Inhibition of IL-23	SC formulation: CD, PSA, PsO, UC
		IV formulation: CD, UC
<b>Tremfya®</b> (guselkumab SC injection, guselkumab IV infusion)	Inhibition of IL-23	SC formulation: CD, PsA, PsO, UC
		IV formulation: CD, UC
<b>Entyvio®</b> (vedolizumab IV infusion, vedolizumab SC injection)	Integrin receptor antagonist	CD, UC
<b>Oral Therapies/Targeted Synthetic Oral Small Molecule Drugs</b>		
<b>Otezla®</b> (apremilast tablets)	Inhibition of PDE4	PsO, PsA
<b>Otezla XR™</b> (apremilast extended-release tablets)	Inhibition of PDE4	PsO, PsA
<b>Cibinqo™</b> (abrocitinib tablets)	Inhibition of JAK pathways	AD
<b>Olumiant®</b> (baricitinib tablets)	Inhibition of JAK pathways	RA, AA
<b>Litfulo®</b> (ritlecitinib capsules)	Inhibition of JAK pathways	AA
<b>Leqselvi®</b> (deuruxolitinib tablets)	Inhibition of JAK pathways	AA
<b>Rinvoq®</b> (upadacitinib extended-release tablets)	Inhibition of JAK pathways	AD, AS, nr-axSpA, RA, PsA, CD, UC
<b>Rinvoq® LQ</b> (upadacitinib oral solution)	Inhibition of JAK pathways	PsA, PJIA
<b>Sotykto®</b> (deucravacitinib tablets)	Inhibition of TYK2	PsO
<b>Xeljanz®</b> (tofacitinib tablets/oral solution)	Inhibition of JAK pathways	RA, PJIA, PsA, UC
<b>Xeljanz® XR</b> (tofacitinib extended-release tablets)	Inhibition of JAK pathways	RA, PsA, UC

<b>Zeposia®</b> (ozanimod tablets)	Sphingosine 1 phosphate receptor modulator	UC
<b>Velsipity®</b> (etrasimod tablets)	Sphingosine 1 phosphate receptor modulator	UC

\* Not an all-inclusive list of indications. Refer to the prescribing information for the respective agent for FDA-approved indications; SC – Subcutaneous; TNF – Tumor necrosis factor; AS – Ankylosing spondylitis; CD – Crohn's disease; JIA – Juvenile idiopathic arthritis; PsO – Plaque psoriasis; PsA – Psoriatic arthritis; RA – Rheumatoid arthritis; UC – Ulcerative colitis; nr-axSpA – Non-radiographic axial spondyloarthritis; IV – Intravenous, PJA – Polyarticular juvenile idiopathic arthritis; IL – Interleukin; SJIA – Systemic juvenile idiopathic arthritis; ^ Off-label use of Kineret in JIA supported in guidelines; ERA – Enthesitis-related arthritis; DMARD – Disease-modifying antirheumatic drug; PDE4 – Phosphodiesterase 4; JAK – Janus kinase; AD – Atopic dermatitis; AA – Alopecia areata; TYK2 – Tyrosine kinase 2.

---

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2025 The Cigna Group.